Daiichi Sankyo sale of 8.93% of Sun Pharma

Overview:

• Daiichi Sankyo has sold 8.93% of the share capital of Sun Pharma.
• Sun Pharma is a generic pharmaceutical company and is the 8th largest company listed on the BSE by market capitalization.
• Goldman sachs acted as bookrunner on the deal.
• Daiichi entered the Indian pharmaceutical market through the acquisition of Ranbaxy Laboratories for $4.6 billion in 2008.

Katrin Kostadinova - Data analyst